Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
February 19 2020 - 4:00PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led
biopharmaceutical company focused on immuno-inflammatory diseases,
today announced it will report financial results for the fourth
quarter and full year 2019, Tuesday, February 25th, after U.S.
financial markets close.
Management will conduct a conference call at 5:00 PM ET on the
same day to discuss Aclaris’ financial results and provide a
general business update. The conference call will be webcast live
over the Internet and can be accessed by logging on to the
“Investors” page of the Aclaris Therapeutics website,
www.aclaristx.com, prior to the event. A replay of the webcast will
be archived on the Aclaris Therapeutics website for 30 days
following the call.
To participate on the live call, please dial (844)
776-7782 (domestic) or (661) 378-9535 (international), and
reference conference ID 9958112 prior to the start of the
call.
About Aclaris Therapeutics, Inc.Aclaris
Therapeutics, Inc. is a physician-led biopharmaceutical company
committed to addressing the needs of patients with
immuno-inflammatory diseases who lack satisfactory treatment
options. The company’s diverse and multi-stage portfolio includes
one late-stage investigational drug candidate and a pipeline
powered by a robust R&D engine exploring protein kinase
regulation. For additional information, please visit
www.aclaristx.com and follow Aclaris on LinkedIn or Twitter
@aclaristx.
Aclaris ContactMichael Tung, M.D.Senior Vice
President Corporate Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2024 to May 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From May 2023 to May 2024